Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition

Patent metadata

Field	Value
Publication number	US-2016003808-A1
Application number	US-201414775861-A
Country	US
Kind code	A1
Filing date	Mar 7, 2014
Priority date	Mar 14, 2013
Publication date	Jan 7, 2016
Grant date	—

Abstract

The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition (EMT), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of diseases associated with epithelial mesenchymal transition, in particular fibrotic disease and cancer. The invention further provides in vitro methods for inhibition of epithelial mesenchymal transition.

First claim

1 . A method for identifying a compound useful for the treatment of a disease associated with epithelial mesenchymal transition, said method comprising:
a) contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21-22, 18-20 and 23-34, functional fragments and derivatives thereof, or with a cell expressing said polypeptide; b) determining a binding affinity of the test compound to said polypeptide, or measuring expression, amount or an activity of said polypeptide; c) contacting the test compound with a population of epithelial cells; d) measuring a property related to epithelial mesenchymal transition; and e) identifying a compound capable of capable of inhibiting of epithelial mesenchymal transition and demonstrating binding affinity to said polypeptide or reducing or inhibiting the expression, amount or an activity of said polypeptide.

2 . (canceled)

3 . (canceled)

4 . A method for identifying a compound inhibiting epithelial mesenchymal transition (EMT), said method comprising:
a) contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21-22, 18-20 and 23-34, functional fragments and functional derivatives thereof or with a nucleic acid encoding an amino acid selected from the group consisting of SEQ ID NOs: 21-22, 18-20 and 23-34 or a functional derivative thereof; b) measuring the expression or an activity of said polypeptide; c) contacting the test compound with a population of epithelial cells; d) measuring a property related to EMT; and e) identifying a compound inhibiting EMT and inhibiting the expression or an activity of said polypeptide.

5 . (canceled)

6 . The method according to claim 4 , wherein the nucleic acid is selected from the group consisting of SEQ ID NOs: 4-5, 1-3 and 6-17.

7 . The method of claim 1 , wherein said disease is a fibrotic disease.

8 . The method of claim 1 , wherein said disease is a cancer.

9 . The method according to claim 1 or 4 , which additionally comprises the step of comparing the compound to be tested to a control.

10 . The method of claim 1 or 4 , wherein said polypeptide is coupled to a detectable label.

11 . The method according to claim 1 or 4 , wherein said polypeptide sequence in steps (a) and (b) is present in an in vitro cell-free preparation.

12 . The method according to claim 1 or 4 , wherein said polypeptide sequence in steps (a) and (b) is present in a cell.

13 . The method according to claim 1 , wherein the cell naturally expresses said polypeptide.

14 . The method according to claim 1 , wherein the cell has been engineered so as to express said polypeptide.

15 . (canceled)

16 . The method of claim 1 , wherein said cell is an epithelial cell.

17 . (canceled)

18 . The method according to claim 16 , wherein said cell is a human bronchial epithelial cell.

19 . The method of claim 1 or 4 , wherein said property is the inhibition of release and/or expression of a marker of epithelial mesenchymal transition (EMT marker).

20 . The method of claim 19 wherein said property is the expression and/or release of a marker selected from the group consisting of matrix Metalloproteases (MMPs), cellular fibronectin (FN), E-cadherin, soluble fibronectin, and vimentin.

21 . (canceled)

22 . The method according to claim 16 wherein said cell has been triggered by a factor which induces epithelial mesenchymal transition (EMT inducing factor).

23 . The method according to claim 22 , wherein said EMT inducing factor is selected from a group consisting of TGFβ, IL-1β, TNFα, and a bacterial challenge.

24 . (canceled)

25 . The method according to claim 1 , wherein said test compound is selected from the group consisting of an antisense polynucleotide, a ribozyme, short-hairpin RNA (shRNA), microRNA (miRNA) and a small interfering RNA (siRNA).

26 . The method according to claim 25 , wherein said test compound comprises a nucleic acid sequence complementary to, or engineered from, a naturally-occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 4-5, 1-3 and 6-17.

27 . (canceled)

28 . (canceled)

29 . The method according to claim 25 , wherein said antisense polynucleotide, said siRNA or said shRNA comprise an antisense strand of 17-25 nucleotides complementary to a sense strand, wherein said sense strand is selected from 17-25 continuous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 4-5, 1-3 and 6-17.

30 . (canceled)

31 . The method according to claim 1 or 4 , wherein said compound is an antibody or an antibody fragment.

32 . A method for treatment of a disease associated with epithelial mesenchymal transition in a mammal comprising administering to said mammal a pharmaceutical composition comprising an antibody or a fragment thereof specifically binding to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21-22, 18-20 and 23-34, or comprising an agent selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), microRNA (miRNA) and a short-hairpin RNA (shRNA), wherein said agent comprises a nucleic acid sequence complementary to, or engineered from, a naturally-occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 4-5, 1-3 and 6-17.

33 . The method according to claim 32 wherein said antagonist is a monoclonal antibody.

34 . The method according to claim 32 wherein said antagonist is a single chain antibody.

35 . (canceled)

36 . The method according to claim 32 , wherein said disease is a fibrotic disease or cancer.

37 . The method according to claim 32 , wherein said disease is selected from idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, bleomycin induced pulmonary fibrosis, chronic asthma, silicosis, asbestos induced pulmonary fibrosis, acute respiratory distress syndrome (ARDS), kidney fibrosis, tubulointerstitium fibrosis, glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathy, hypertension, Alport syndrome, gut fibrosis, liver fibrosis, cirrhosis, alcohol induced liver fibrosis, toxic/drug induced liver fibrosis, hemochromatosis, nonalcoholic steatohepatitis (NASH), biliary duct injury, primary biliary cirrhosis, infection induced liver fibrosis, viral induced liver fibrosis, autoimmune hepatitis, corneal

Assignees

• Galapagos Nv

Inventors

• Janssen Richard Antonius Jozef
• Lekkerkerker Annemarie Nicolete
• Aarbiou Jamil

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title